Sarah Louise Gordon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sarah Louise Gordon has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Holly Melland
Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Faculty of Pharmacy and Pharmaceutical Sciences Monash University Parkville Victoria Australia
6 shared publications - Kate Baker
University of Cambridge
4 shared publications - Michael Alan Cousin
Centre for Discovery Brain Sciences University of Edinburgh Edinburgh UK
4 shared publications Holly Melland
3 shared publicationsCallista B. Harper
Centre for Discovery Brain Sciences, Hugh Robson Building, University of Edinburgh, George Square, Edinburgh, Scotland, UK, EH8 9XD
2 shared publicationsElyas H. Arvell
The Florey Institute of Neuroscience and Mental Health The University of Melbourne Parkville Victoria Australia
2 shared publications
Latest Publications
- Open Access
- 8 October 2026
- Published by Wiley in Journal of Neurochemistry
- Vol. 170 (10) , e70568
Increased Expression of α‐Synuclein Impairs Trafficking of the Essential SNARE Protein Synaptobrevin‐2
α‐Synuclein is a presynaptic protein that has been extensively studied for its role in Parkinson's disease. Multiplication and missense variants in the gene encoding α‐synuclein are causes of familial PD, and aggregated α‐synuclein is a major component of Lewy bodies and Lewy neurites, the histopathological hallmark of the disease. However, the native function of α‐synuclein remains unclear, though several lines of evidence suggest it modulates presynaptic function. α‐Synuclein binds the vesicular SNARE protein synaptobrevin‐2/VAMP2, and increased levels of α‐synuclein potentiate SNARE complex levels without impacting exocytic rate. Given the essential role of synaptobrevin‐2 in synaptic function we sought to examine how increased expression of α‐synuclein, at levels observed in familial synucleinopathies with SNCA triplication, impacts the trafficking of this essential SNARE protein. Modest (approximately 2‐fold) overexpression of α‐synuclein in cultured murine hippocampal neurons caused a slowing in the endocytic retrieval of synaptobrevin‐2, without impacting either the targeting of the protein to synapses or altering endocytosis. We also show that α‐synuclein is not working antagonistically with the synaptobrevin‐2 chaperone synaptophysin, and likely acts at least partially via direct binding to synaptobrevin‐2. Finally, increased expression of α‐synuclein induces synaptic depression upon repeated neuronal depolarisation, in a manner requiring binding to synaptobrevin‐2. We reveal α‐synuclein as a modulator of synaptobrevin‐2 endocytic trafficking and highlight perturbed SNARE protein trafficking as a potential contributor to synaptic dysfunction and neuronal health in Parkinson's disease. image
- 8 October 2026
- Published by Wiley in Journal of Neurochemistry
- Vol. 170 (10) , e70568
Open AccessIncreased Expression of α‐Synuclein Impairs Trafficking of the Essential SNARE Protein Synaptobrevin‐2
α‐Synuclein is a presynaptic protein that has been extensively studied for its role in Parkinson's disease. Multiplication and missense variants in the gene encoding α‐synuclein are causes of familial PD, and aggregated α‐synuclein is a major component of Lewy bodies and Lewy neurites, the histopathological hallmark of the disease. However, the native function of α‐synuclein remains unclear, though several lines of evidence suggest it modulates presynaptic function. α‐Synuclein binds the vesicular SNARE protein synaptobrevin‐2/VAMP2, and increased levels of α‐synuclein potentiate SNARE complex levels without impacting exocytic rate. Given the essential role of synaptobrevin‐2 in synaptic function we sought to examine how increased expression of α‐synuclein, at levels observed in familial synucleinopathies with SNCA triplication, impacts the trafficking of this essential SNARE protein. Modest (approximately 2‐fold) overexpression of α‐synuclein in cultured murine hippocampal neurons caused a slowing in the endocytic retrieval of synaptobrevin‐2, without impacting either the targeting of the protein to synapses or altering endocytosis. We also show that α‐synuclein is not working antagonistically with the synaptobrevin‐2 chaperone synaptophysin, and likely acts at least partially via direct binding to synaptobrevin‐2. Finally, increased expression of α‐synuclein induces synaptic depression upon repeated neuronal depolarisation, in a manner requiring binding to synaptobrevin‐2. We reveal α‐synuclein as a modulator of synaptobrevin‐2 endocytic trafficking and highlight perturbed SNARE protein trafficking as a potential contributor to synaptic dysfunction and neuronal health in Parkinson's disease. image
- 8 September 2026
- Published by Society for Neuroscience in The Journal of Neuroscience
- Vol. 46 (42)
Phosphorylation of a-Synuclein Directs Trafficking of the v-SNARE Synaptobrevin-2
A-Synuclein has been extensively studied for its role in Parkinson's disease; however, its native function remains unclear. Several lines of evidence suggest it modulates presynaptic function. As many presynaptic proteins have their functions regulated by phosphorylation, we sought to determine whether a-synuclein, a known phosphoprotein, might similarly have phospho-dependent roles. We identified two residues in a-synuclein, Ser42 and Thr81, that undergo activity-dependent phosphorylation in response to neuronal depolarization. We employed a molecular replacement strategy, introducing a-synuclein phosphovariants into neuronal cultures from a-synuclein knock-out mice (of either sex), and revealed that ablating phosphorylation at Thr81 altered the subcellular distribution of synaptobrevin-2/VAMP2, a crucial fusogenic vesicular SNARE protein and known binding partner of a-synuclein. Ablating phosphorylation of a-synuclein at Thr81 specifically accelerated endocytic retrieval of synaptobrevin-2 during stimulation without impacting global endocytosis, evoked exocytosis, or the size of the recycling pool. Conversely, mimicking phosphorylation at Thr81 augmented poststimulation retrieval of synaptobrevin-2. This suggests that activity-dependent phosphorylation of Thr81 modulates the trafficking of synaptobrevin-2 to direct its retrieval via different endocytic pathways, thereby impacting presynaptic functionality and plasticity.
- 8 September 2026
- Published by Society for Neuroscience in The Journal of Neuroscience
- Vol. 46 (42)
Phosphorylation of a-Synuclein Directs Trafficking of the v-SNARE Synaptobrevin-2
A-Synuclein has been extensively studied for its role in Parkinson's disease; however, its native function remains unclear. Several lines of evidence suggest it modulates presynaptic function. As many presynaptic proteins have their functions regulated by phosphorylation, we sought to determine whether a-synuclein, a known phosphoprotein, might similarly have phospho-dependent roles. We identified two residues in a-synuclein, Ser42 and Thr81, that undergo activity-dependent phosphorylation in response to neuronal depolarization. We employed a molecular replacement strategy, introducing a-synuclein phosphovariants into neuronal cultures from a-synuclein knock-out mice (of either sex), and revealed that ablating phosphorylation at Thr81 altered the subcellular distribution of synaptobrevin-2/VAMP2, a crucial fusogenic vesicular SNARE protein and known binding partner of a-synuclein. Ablating phosphorylation of a-synuclein at Thr81 specifically accelerated endocytic retrieval of synaptobrevin-2 during stimulation without impacting global endocytosis, evoked exocytosis, or the size of the recycling pool. Conversely, mimicking phosphorylation at Thr81 augmented poststimulation retrieval of synaptobrevin-2. This suggests that activity-dependent phosphorylation of Thr81 modulates the trafficking of synaptobrevin-2 to direct its retrieval via different endocytic pathways, thereby impacting presynaptic functionality and plasticity.
- Open Access
- 31 October 2024
- Published by Elsevier in EBioMedicine
- Vol. 109, 105416
Correlation between evoked neurotransmitter release and adaptive functions in SYT1-associated neurodevelopmental disorder
- 31 October 2024
- Published by Elsevier in EBioMedicine
- Vol. 109, 105416
Open AccessCorrelation between evoked neurotransmitter release and adaptive functions in SYT1-associated neurodevelopmental disorder
- Open Access
Adaptive functions correlate with evoked neurotransmitter release in SYT1-associated neurodevelopmental disorder
Pathogenic missense variants in the essential synaptic vesicle protein synaptotagmin-1 (SYT1) cause a neurodevelopmental disorder that is characterised by motor delay and intellectual disability, hyperkinetic movement disorder, episodic agitation, and visual impairments. SYT1 is the presynaptic calcium sensor that both triggers and drives synchronous neurotransmitter release. We have previously shown that pathogenic variants around the calcium-sensing region of the critical C2B domain decrease synaptic vesicle exocytosis in neurons. Here we show that recently identified variants within the facilitatory C2A domain of the protein (L159R, T196K, E209K, E219Q), as well as additional variants in the C2B domain (M303V, S309P, Y365C, G369D), share this underlying pathogenic mechanism, causing a graded and variant-dependent dominant-negative impairment in exocytosis. We establish that the extent of disruption to exocytosis in vitro correlates with neurodevelopmental impacts of this disorder. Specifically, the severity of motor and communication impairments exhibited by individuals harbouring these variants correlates with multiple measures of exocytic impairment. Together, this suggests that there is a genotype-function-phenotype relationship in SYT1-associated neurodevelopmental disorder, centring impaired evoked neurotransmitter release as a common pathogenic driver of this disorder. Moreover, this points toward a direct link between control of neurotransmitter release and development of adaptive functions, and provides a tractable target for therapeutic amelioration.
Open AccessAdaptive functions correlate with evoked neurotransmitter release in SYT1-associated neurodevelopmental disorder
Pathogenic missense variants in the essential synaptic vesicle protein synaptotagmin-1 (SYT1) cause a neurodevelopmental disorder that is characterised by motor delay and intellectual disability, hyperkinetic movement disorder, episodic agitation, and visual impairments. SYT1 is the presynaptic calcium sensor that both triggers and drives synchronous neurotransmitter release. We have previously shown that pathogenic variants around the calcium-sensing region of the critical C2B domain decrease synaptic vesicle exocytosis in neurons. Here we show that recently identified variants within the facilitatory C2A domain of the protein (L159R, T196K, E209K, E219Q), as well as additional variants in the C2B domain (M303V, S309P, Y365C, G369D), share this underlying pathogenic mechanism, causing a graded and variant-dependent dominant-negative impairment in exocytosis. We establish that the extent of disruption to exocytosis in vitro correlates with neurodevelopmental impacts of this disorder. Specifically, the severity of motor and communication impairments exhibited by individuals harbouring these variants correlates with multiple measures of exocytic impairment. Together, this suggests that there is a genotype-function-phenotype relationship in SYT1-associated neurodevelopmental disorder, centring impaired evoked neurotransmitter release as a common pathogenic driver of this disorder. Moreover, this points toward a direct link between control of neurotransmitter release and development of adaptive functions, and provides a tractable target for therapeutic amelioration.
- Open Access
Delineation of the pathogenic presynaptic mechanisms of synaptotagmin-1 variants
Missense variants in the presynaptic calcium sensor synaptotagmin-1 (SYT1) are associated with an autosomal dominant neurodevelopmental disorder (NDD). These cause dominant-negative impairment of evoked neurotransmitter release in a mutation-specific manner; however, whether NDD-associated variants also perturb the auxiliary functions of SYT1 remains unknown. We investigated whether the expression of SYT1 variants in cultured hippocampal neurons altered either action potential-independent spontaneous synaptic vesicle exocytosis or synaptic vesicle endocytosis. SYT1 variants did not induce dominant-negative impairment of either process, confirming that defective evoked exocytosis is the major pathogenic mechanism of SYT1-associated NDD. To examine the differential impacts of human variants on evoked exocytosis, both NDD-associated and strategic mutations were used to explore the functional importance of two distinct Ca 2+ -binding residues in the C2B domain. We show that both the nature of the amino acid change and the specific residues targeted determine the severity of exocytic disturbance. Together, this work informs understanding of SYT1 function and further clarifies potential mechanistic targets for treating SYT1-associated NDD.
Open AccessDelineation of the pathogenic presynaptic mechanisms of synaptotagmin-1 variants
Missense variants in the presynaptic calcium sensor synaptotagmin-1 (SYT1) are associated with an autosomal dominant neurodevelopmental disorder (NDD). These cause dominant-negative impairment of evoked neurotransmitter release in a mutation-specific manner; however, whether NDD-associated variants also perturb the auxiliary functions of SYT1 remains unknown. We investigated whether the expression of SYT1 variants in cultured hippocampal neurons altered either action potential-independent spontaneous synaptic vesicle exocytosis or synaptic vesicle endocytosis. SYT1 variants did not induce dominant-negative impairment of either process, confirming that defective evoked exocytosis is the major pathogenic mechanism of SYT1-associated NDD. To examine the differential impacts of human variants on evoked exocytosis, both NDD-associated and strategic mutations were used to explore the functional importance of two distinct Ca 2+ -binding residues in the C2B domain. We show that both the nature of the amino acid change and the specific residues targeted determine the severity of exocytic disturbance. Together, this work informs understanding of SYT1 function and further clarifies potential mechanistic targets for treating SYT1-associated NDD.
- Open Access
- 8 October 2021
- Published by Frontiers Media SA in Frontiers in Molecular Neuroscience
- Vol. 14
Postsynaptic Neuroligin-1 Mediates Presynaptic Endocytosis During Neuronal Activity
Fast, high-fidelity neurotransmission and synaptic efficacy requires tightly regulated coordination of pre- and postsynaptic compartments and alignment of presynaptic release sites with postsynaptic receptor nanodomains. Neuroligin-1 (Nlgn1) is a postsynaptic cell-adhesion protein exclusively localised to excitatory synapses that is crucial for coordinating the transsynaptic alignment of presynaptic release sites with postsynaptic AMPA receptors as well as postsynaptic transmission and plasticity. However, little is understood about whether the postsynaptic machinery can mediate the molecular architecture and activity of the presynaptic nerve terminal, and thus it remains unclear whether there are presynaptic contributions to Nlgn1-dependent control of signalling and plasticity. Here, we employed a presynaptic reporter of neurotransmitter release and synaptic vesicle dynamics, synaptophysin-pHluorin (sypHy), to directly assess the presynaptic impact of loss of Nlgn1. We show that lack of Nlgn1 had no effect on the size of the readily releasable or entire recycling pool of synaptic vesicles, nor did it impact exocytosis. However, we observed significant changes in the retrieval of synaptic vesicles by compensatory endocytosis, specifically during activity. Our data extends growing evidence that synaptic adhesion molecules critical for forming transsynaptic scaffolds are also important for regulating activity-induced endocytosis at the presynapse.
- 8 October 2021
- Published by Frontiers Media SA in Frontiers in Molecular Neuroscience
- Vol. 14
Open AccessPostsynaptic Neuroligin-1 Mediates Presynaptic Endocytosis During Neuronal Activity
Fast, high-fidelity neurotransmission and synaptic efficacy requires tightly regulated coordination of pre- and postsynaptic compartments and alignment of presynaptic release sites with postsynaptic receptor nanodomains. Neuroligin-1 (Nlgn1) is a postsynaptic cell-adhesion protein exclusively localised to excitatory synapses that is crucial for coordinating the transsynaptic alignment of presynaptic release sites with postsynaptic AMPA receptors as well as postsynaptic transmission and plasticity. However, little is understood about whether the postsynaptic machinery can mediate the molecular architecture and activity of the presynaptic nerve terminal, and thus it remains unclear whether there are presynaptic contributions to Nlgn1-dependent control of signalling and plasticity. Here, we employed a presynaptic reporter of neurotransmitter release and synaptic vesicle dynamics, synaptophysin-pHluorin (sypHy), to directly assess the presynaptic impact of loss of Nlgn1. We show that lack of Nlgn1 had no effect on the size of the readily releasable or entire recycling pool of synaptic vesicles, nor did it impact exocytosis. However, we observed significant changes in the retrieval of synaptic vesicles by compensatory endocytosis, specifically during activity. Our data extends growing evidence that synaptic adhesion molecules critical for forming transsynaptic scaffolds are also important for regulating activity-induced endocytosis at the presynapse.
- Open Access
Expanding the genotype and phenotype spectrum of SYT1 -associated neurodevelopmental disorder
Purpose: Synaptotagmin-1 (SYT1) is a critical mediator of neurotransmitter release in the central nervous system. Previously reported missense SYT1 variants in the C2B domain are associated with severe intellectual disability, movement disorders, behavioural disturbance and EEG abnormalities. Here, we expand the genotypes and phenotypes and identify discriminating features of this disorder. Methods: We describe 22 individuals with 15 de novo missense SYT1 variants. Evidence for pathogenicity is discussed, including ACMG criteria, known structure-function relationships, and molecular dynamics simulations. Quantitative behavioural data for 14 cases are compared to other monogenic neurodevelopmental disorders. Results: Four variants lie in the C2A domain with the remainder in the C2B. We classify 6 variants as pathogenic, 4 as likely pathogenic, and 5 as variants of uncertain significance. Prevalent clinical phenotypes include delayed developmental milestones, ophthalmic problems, abnormal EEG, movement disorders and sleep disturbance. Discriminating behavioural characteristics were severity of motor and communication impairment, presence of motor stereotypies and mood instability. Conclusion: SYT1 variants associated with neurodevelopmental disorder extend beyond previously reported regions, and the phenotypic spectrum encompasses a broader range of severity than initially reported. This work guides diagnosis and molecular understanding of this rare neurodevelopmental disorder, and highlights a key role for SYT1 function in emotional regulation, motor control and emergent cognitive function.
Open AccessExpanding the genotype and phenotype spectrum of SYT1 -associated neurodevelopmental disorder
Purpose: Synaptotagmin-1 (SYT1) is a critical mediator of neurotransmitter release in the central nervous system. Previously reported missense SYT1 variants in the C2B domain are associated with severe intellectual disability, movement disorders, behavioural disturbance and EEG abnormalities. Here, we expand the genotypes and phenotypes and identify discriminating features of this disorder. Methods: We describe 22 individuals with 15 de novo missense SYT1 variants. Evidence for pathogenicity is discussed, including ACMG criteria, known structure-function relationships, and molecular dynamics simulations. Quantitative behavioural data for 14 cases are compared to other monogenic neurodevelopmental disorders. Results: Four variants lie in the C2A domain with the remainder in the C2B. We classify 6 variants as pathogenic, 4 as likely pathogenic, and 5 as variants of uncertain significance. Prevalent clinical phenotypes include delayed developmental milestones, ophthalmic problems, abnormal EEG, movement disorders and sleep disturbance. Discriminating behavioural characteristics were severity of motor and communication impairment, presence of motor stereotypies and mood instability. Conclusion: SYT1 variants associated with neurodevelopmental disorder extend beyond previously reported regions, and the phenotypic spectrum encompasses a broader range of severity than initially reported. This work guides diagnosis and molecular understanding of this rare neurodevelopmental disorder, and highlights a key role for SYT1 function in emotional regulation, motor control and emergent cognitive function.
- Open Access
Postsynaptic neuroligin-1 mediates presynaptic endocytosis during neuronal activity
Fast, high-fidelity neurotransmission and synaptic efficacy requires tightly regulated coordination of pre- and postsynaptic compartments and alignment of presynaptic release sites with postsynaptic receptor nanodomains. Neuroligin-1 (Nlgn-1) is a postsynaptic cell-adhesion protein exclusively localised to excitatory synapses that is crucial for coordinating the transsynaptic alignment of presynaptic release sites with postsynaptic AMPA receptors as well as postsynaptic transmission and plasticity. However, little is understood about whether the postsynaptic machinery can mediate the molecular architecture and activity of the presynaptic nerve terminal, and thus it remains unclear whether there are presynaptic contributions to Nlgn1-dependent control of signalling and plasticity. Here, we employed a presynaptic reporter of neurotransmitter release and synaptic vesicle dynamics, synaptophysin-pHluorin (sypHy), to directly assess the presynaptic impact of loss of Nlgn1. We show that lack of Nlgn1 had no effect on the size of the readily releasable or entire recycling pool of synaptic vesicles, nor did it impact exocytosis. However, we observed significant changes in the retrieval of synaptic vesicles by compensatory endocytosis, specifically during activity. Our data extends growing evidence that synaptic adhesion molecules critical for forming transsynaptic scaffolds are also important for regulating activity-induced endocytosis at the presynapse.
Open AccessPostsynaptic neuroligin-1 mediates presynaptic endocytosis during neuronal activity
Fast, high-fidelity neurotransmission and synaptic efficacy requires tightly regulated coordination of pre- and postsynaptic compartments and alignment of presynaptic release sites with postsynaptic receptor nanodomains. Neuroligin-1 (Nlgn-1) is a postsynaptic cell-adhesion protein exclusively localised to excitatory synapses that is crucial for coordinating the transsynaptic alignment of presynaptic release sites with postsynaptic AMPA receptors as well as postsynaptic transmission and plasticity. However, little is understood about whether the postsynaptic machinery can mediate the molecular architecture and activity of the presynaptic nerve terminal, and thus it remains unclear whether there are presynaptic contributions to Nlgn1-dependent control of signalling and plasticity. Here, we employed a presynaptic reporter of neurotransmitter release and synaptic vesicle dynamics, synaptophysin-pHluorin (sypHy), to directly assess the presynaptic impact of loss of Nlgn1. We show that lack of Nlgn1 had no effect on the size of the readily releasable or entire recycling pool of synaptic vesicles, nor did it impact exocytosis. However, we observed significant changes in the retrieval of synaptic vesicles by compensatory endocytosis, specifically during activity. Our data extends growing evidence that synaptic adhesion molecules critical for forming transsynaptic scaffolds are also important for regulating activity-induced endocytosis at the presynapse.
- Open Access
- 17 March 2021
- Published by Wiley in Journal of Neurochemistry
- Vol. 157 (2) , 102-106
Preface to the Special Issue “Presynaptic Dysfunction and Disease”
The synapse is formed between a presynapse (which releases neurotransmitter) and the postsynapse (which transduces this chemical signal). Over the past decade, presynaptic dysfunction has emerged as a key mediator of a series of neurodevelopmental and neurodegenerative disorders. This special issue will highlight some of the important presynaptic molecules and mechanisms that are disrupted in these conditions and reveal potential routes for therapy.
- 17 March 2021
- Published by Wiley in Journal of Neurochemistry
- Vol. 157 (2) , 102-106
Open AccessPreface to the Special Issue “Presynaptic Dysfunction and Disease”
The synapse is formed between a presynapse (which releases neurotransmitter) and the postsynapse (which transduces this chemical signal). Over the past decade, presynaptic dysfunction has emerged as a key mediator of a series of neurodevelopmental and neurodegenerative disorders. This special issue will highlight some of the important presynaptic molecules and mechanisms that are disrupted in these conditions and reveal potential routes for therapy.
- Open Access
- 11 September 2020
- Published by Wiley in Journal of Neurochemistry
- Vol. 157 (2) , 130-164
Disorders of synaptic vesicle fusion machinery
The revolution in genetic technology has ushered in a new age for our understanding of the underlying causes of neurodevelopmental, neuromuscular and neurodegenerative disorders, revealing that the presynaptic machinery governing synaptic vesicle fusion is compromised in many of these neurological disorders. This builds upon decades of research showing that disturbance to neurotransmitter release via toxins can cause acute neurological dysfunction. In this review, we focus on disorders of synaptic vesicle fusion caused either by toxic insult to the presynapse or alterations to genes encoding the key proteins that control and regulate fusion: the SNARE proteins (synaptobrevin, syntaxin‐1 and SNAP‐25), Munc18, Munc13, synaptotagmin, complexin, CSPα, α‐synuclein, PRRT2 and tomosyn. We discuss the roles of these proteins and the cellular and molecular mechanisms underpinning neurological deficits in these disorders. image
- 11 September 2020
- Published by Wiley in Journal of Neurochemistry
- Vol. 157 (2) , 130-164
Open AccessDisorders of synaptic vesicle fusion machinery
The revolution in genetic technology has ushered in a new age for our understanding of the underlying causes of neurodevelopmental, neuromuscular and neurodegenerative disorders, revealing that the presynaptic machinery governing synaptic vesicle fusion is compromised in many of these neurological disorders. This builds upon decades of research showing that disturbance to neurotransmitter release via toxins can cause acute neurological dysfunction. In this review, we focus on disorders of synaptic vesicle fusion caused either by toxic insult to the presynapse or alterations to genes encoding the key proteins that control and regulate fusion: the SNARE proteins (synaptobrevin, syntaxin‐1 and SNAP‐25), Munc18, Munc13, synaptotagmin, complexin, CSPα, α‐synuclein, PRRT2 and tomosyn. We discuss the roles of these proteins and the cellular and molecular mechanisms underpinning neurological deficits in these disorders. image